Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRINTEC vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 15 years of age who have achieved menarche and are seeking an oral contraceptive
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Ethinyl estradiol: 13 ± 3 hours (variable, influenced by CYP3A4 activity); Norgestimate: 1.5-2 hours (rapidly converted to norelgestromin); Norelgestromin: 12-20 hours (active metabolite); clinical context: dosing interval of 24 hours supports once-daily administration.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol is metabolized primarily by CYP3A4; norgestimate is rapidly metabolized to norelgestromin and norgestrel via first-pass metabolism.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: approximately 50-60% (metabolites, primarily glucuronide conjugates), Fecal: approximately 30-40% (biliary excretion of metabolites), with minimal unchanged drug in urine (<5%).
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Ethinyl estradiol: >97% bound to albumin; Norgestimate/norelgestromin: 99% bound to albumin and sex hormone-binding globulin (SHBG).
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Ethinyl estradiol: 2.5-4.0 L/kg; Norgestimate: not determined (extensive tissue distribution); clinical meaning: reflects distribution into total body water and tissues.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Ethinyl estradiol: 38-48% due to first-pass metabolism; Norgestimate: 100% (prodrug, rapidly hydrolyzed in gut wall and liver).
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use caution.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). No data for mild impairment; use with caution.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Safety and efficacy have not been established in postmenarchal pediatric patients. Use after first menses; dosing same as adults.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for use in postmenopausal women. No specific dose adjustment needed for elderly patients beyond contraindications.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptive use. Risk increases with age (>35 years) and number of cigarettes smoked. Women over 35 who smoke should not use combined oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders,Increased risk of myocardial infarction and stroke, especially in smokers,Increased risk of hepatic neoplasia,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Avoid grapefruit juice as it may increase estrogen levels and risk of adverse effects. No other significant food interactions are known; maintain consistent dietary habits to minimize gastrointestinal side effects.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube defects. Second and third trimesters: Fetal genital abnormalities in females (diethylstilbestrol-like effect); potential for long-term reproductive tract changes. Postnatal: Possible increased risk of neurodevelopmental issues.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Excreted in human breast milk with milk-to-plasma ratio approximately 0.5. Potential adverse effects in nursing infant including jaundice and breast enlargement. Use during lactation not recommended unless clearly necessary. May reduce milk production and quality.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustments approved; contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) could reduce efficacy if used, but use is contraindicated.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
SPRINTEC (ethinyl estradiol/norgestimate) is a combined oral contraceptive. Prescribe with caution in women with migraine with aura due to increased stroke risk. If a dose is missed, take as soon as remembered; if >24 hours late, use backup contraception for 7 days. Monitor blood pressure at initiation and annually. Discontinue if pregnancy is suspected or confirmed. Advise that antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet daily at the same time each day, in the order directed on the pill pack.,If you miss a pill, refer to the package insert or consult your healthcare provider; use backup contraception as directed.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often improve within a few cycles.,Seek immediate medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,Inform your provider about all medications, including over-the-counter drugs and herbal supplements, especially St. John's Wort.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRINTEC vs ALTAVERA, answered by our medical review team.
SPRINTEC is a Oral Contraceptive that works by Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRINTEC and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRINTEC is: One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRINTEC and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRINTEC is classified as Category C. FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube def. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.